- Home
- PBPB vs NGNE Comparison
PBPB vs NGNE Comparison
Compare PBPB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- NGNE
- Stock Information
- Founded
- PBPB 1977
- NGNE 2003
- Country
- PBPB United States
- NGNE United States
- Employees
- PBPB N/A
- NGNE N/A
- Industry
- PBPB Restaurants
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- NGNE Health Care
- Exchange
- PBPB Nasdaq
- NGNE Nasdaq
- Market Cap
- PBPB 305.0M
- NGNE 325.3M
- IPO Year
- PBPB 2013
- NGNE N/A
- Fundamental
- Price
- PBPB $12.94
- NGNE $18.48
- Analyst Decision
- PBPB Strong Buy
- NGNE Strong Buy
- Analyst Count
- PBPB 2
- NGNE 7
- Target Price
- PBPB $17.50
- NGNE $41.86
- AVG Volume (30 Days)
- PBPB 257.0K
- NGNE 110.1K
- Earning Date
- PBPB 08-06-2025
- NGNE 08-11-2025
- Dividend Yield
- PBPB N/A
- NGNE N/A
- EPS Growth
- PBPB N/A
- NGNE N/A
- EPS
- PBPB 0.35
- NGNE N/A
- Revenue
- PBPB $469,138,000.00
- NGNE N/A
- Revenue This Year
- PBPB $5.28
- NGNE N/A
- Revenue Next Year
- PBPB $4.30
- NGNE N/A
- P/E Ratio
- PBPB $37.36
- NGNE N/A
- Revenue Growth
- PBPB N/A
- NGNE N/A
- 52 Week Low
- PBPB $7.27
- NGNE $6.88
- 52 Week High
- PBPB $13.67
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- PBPB 57.95
- NGNE 35.93
- Support Level
- PBPB $12.78
- NGNE $19.59
- Resistance Level
- PBPB $13.18
- NGNE $20.46
- Average True Range (ATR)
- PBPB 0.38
- NGNE 1.23
- MACD
- PBPB 0.05
- NGNE -0.20
- Stochastic Oscillator
- PBPB 81.10
- NGNE 13.37
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.